Neorx Corp. About
Neorx Corp NeoRx Corporation is engaged in the development
and commercialization of oncology products.
The Company has two clinical-stage product
candidates in development: STR (Skeletal
Targeted Radiotherapy) and NX 473. STR
is a bone-targeting radiopharmaceutical
that delivers radiation directly to cancer
cells in the bone and marrow. STR is being
developed to treat patients with multiple
myeloma and other cancers that arise in
or spread to the bone marrow.NeoRx is
dedicated to the development and commercialization
of oncology products. We have two clinical-stage
product candidates in development -- STR™
and NX 473. Both candidates have been
evaluated in cancer patients, demonstrating
clinical benefits and manageable safety
profiles. STR is a bone-targeting radiopharmaceutical
that delivers radiation directly to cancer
cells in the bone and marrow. We are developing
STR to treat patients with multiple myeloma
and other cancers that arise in or spread
to the bone marrow, such as leukemias,
lymphomas and bone metastases of breast,
prostate and lung cancers. We currently
are conducting a Phase III pivotal clinical
trial of STR with high-dose chemotherapy
and autologous (self-donor) stem cell
transplantation in patients with multiple
myeloma. The study is open to enrollment
of patients with primary refractory multiple
myeloma. We also have submitted a protocol
to the Food and Drug Administration (FDA)
for a Phase II study of STR in patients
with breast cancer metastasized to the
bone. NX 473 is a next-generation platinum
compound designed to improve on the safety
and efficacy of existing platinum therapeutics
for cancer. In early clinical trials,
NX 473 has demonstrated clinical activity
in patients with lung, prostate and ovarian
cancers, as a single agent and in combination
regimens. We have received clearance from
the FDA for our Investigational New Drug
(IND) application for a Phase II study
of NX 473 in patients with small cell
lung cancer. We also plan to conduct a
Phase I/II clinical study of NX 473 in
patients with colorectal cancer. Product
Pipeline for NeoPharm --
LEP ETU Liposomal Paclitaxel-Easy-to-use -- Advanced cancers; including
breast, lung and ovarian NX 473 is a next-generation platinum
compound for cancer treatment. It has
been tested extensively in preclinical
studies, and has been evaluated in more
than 500 patients in Phase I and II clinical
trials. NX 473 has demonstrated activity
as a single agent in patients with lung
cancer, ovarian cancer, and hormone refractory
prostate cancer, More
on Neorx